280 likes | 574 Views
Clinical Research Network West of England. SWAG SSG Haematology and Lymphoma Meeting Wednesday 2 nd November 2016. Clinical Research Network & Cancer Services. West ofEngland. SWAG - Somerset Wiltsire Avon & Gloucestershire South West Children’s Cancer & L eukaemia Research Network.
E N D
Clinical Research Network West of England SWAG SSG Haematology and Lymphoma Meeting Wednesday 2nd November 2016
Clinical Research Network & Cancer Services West ofEngland SWAG - Somerset Wiltsire Avon & Gloucestershire South West Children’s Cancer & Leukaemia Research Network
NIHR CRN – what does it do? • Infrastructure that allows high-quality clinical research to take place in the NHS • Help researchers to set up clinical studies quickly and effectively • Support the life-sciences industry to deliver their research programmes in the NHS • Provide health professionals with research training • Work with patients to ensure their needs are at the very centre of all research activity.
NIHR CRN High Level Objectives • Increase number of participants into NIHR CRN portfolio studies • Target 650,000 in England pa • Target 22,000 in West of England pa • Increase the number of studies that deliver to time and target • Objective 80% • Increase number of commercial studies delivered through network • Reduce NHS study set up times • Reduce time taken to recruit first participant
Local Clinical Research Networks • Translation of national objectives for clinical research • Oversight of research activity within the geography of CRN - West of England in terms of: • Portfolio • Balance, new studies, feasibility, set up, industry trials • Performance • Support, network wide solutions, targets • People • Patient involvement, staff skill mix & flexibility, training, resources
30 Clinical Specialties • Ageing • Anaesthetics & pain • Cancer • Cardiovascular • Children • Critical Care • Dementia & Neurodegenerative • Dermatology • Diabetes • ENT • Gastroenterology • Genetics • Haematology • Health Services • Hepatology • Infectious Diseases • Injuries & Emergencies • Mental Health • Metabolic & Endocrine • Musculoskeletal • Neurological • Opthalmology • Oral & Dental • Primary Care • Public Health • Renal • Reproductive Health • Respiratory • Stroke • Surgery
National Clinical Studies Groups Psychosocial & Survivorship Imaging Adv. panel Breast Cancer CSG Brain Tumours CSG Lung Cancer CSG Palliative & Supportive Care Head & Neck CSG Biomarkers Adv. panel Upper GI Cancer CSG Consumer Liaison Group Sarcoma CSG Colorectal Cancer CSG Melanoma CSG Kidney Cancer CSG Primary Care Lymphoma CSG Bladder Cancer CSG Screening, Prevention & Early Diagnosis Haematol. CSG Testis Cancer CSG Prostate Cancer CSG Gynae Cancer CSG Children’s Cancer & Leukaemia Teenage & Young Adult CTRad (Radiotherapy)
Cancer sub specialty lead role • Communicate and collaborate with clinical colleagues across the network re the portfolio of studies in their sub specialty • Action plan in place to increase access to research • Mapping portfolio across the network • Shared portfolio of studies • Improve referral pathways for research • Encourage more referral for research • Consider economies of scale for rare disease studies • Network wide planning for EOIs • Support and encourage teams to meet study targets
NIHR CRN Objectives for cancer • Recruit 20% of cancer incidence • West of England 1,909 • Recruit 7.5% of cancer incidence into interventional studies • 716 • Include challenging studies • Cancer surgery – 4 recruits per 100,000 population • Radiotherapy – 6 recruits per 100,000 population • Rare cancers (<6 per 100,000) – 12 recruits per 100,000 population • Children & young people – 3 per 100,000 population • Teenagers & young adults – record number of 16-25 year olds approached and/or participating in research
% Recruitment of cancer incidence to interventional studies by Local Clinical Research Network 2016-17
% Recruitment to haematological cancer studies by LCRN 2016-17 to date
SWAG study recruitment 2016-17 to date Lymphoma Haematological cancer
Lymphoma continued NCRN 3245 – Betalutinradioimmunotherapy for treatment of relapsed CD37+NHL . Commercial Target 7. Recruited 6. Open at UHB. Currently suspended.
Studies in set up - Haematology Studies in set up - Lymphoma
Useful links • https://www.crn.nihr.ac.uk/ • National and local network information including training programmes templates, tools, contacts, videos etc • https://odp.nihr.ac.uk/ http:/ • Open data platform. Look at performance across whole CRN including all specialty areas • /csg.ncri.org.uk/portfolio/portfolio-maps/ • View current national portfolio of open, closed and ‘in set up’ cancer studies • https://www.ukctg.nihr.ac.uk/ • See where a study is open across the country • http://public-odp.nihr.ac.uk/ • Search for a study to fit criteria. Good for horizon scanning, eligibility criteria
Contacts • Research Delivery Manager – maxine.taylor@nihr.ac.uk • Cancer portfolio facilitator – sarah.west@nihr.ac.uk